Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Compare brokers on index fund selections, focusing on fund variety, fees, and ease of use to pick the best platform for your needs.
28,035 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Interactive Brokers clients favored Nvidia after its record quarter, purchasing the stock as it pulled back from the ...
Rivian shares surged about 8% after the company unveiled the R2 midsize SUV, signaling a push toward broader market a...
Oil prices push higher as supply fears mount, triggering a broad debt selloff and jittery stock futures. Iran tension...
Retail investors are retreating from crypto while institutions step up exposure, reshaping liquidity and risk. The sh...
A surge of mega IPOs in 2026 is minting new fortunes. Melinda French Gates’ advice for these newcomers centers on gen...
Regulators in Spain are sending a clear message: there will be no extensions for the EU crypto licensing deadline. Th...
A major investor moved a sizable stake in Hinge Health, triggering questions about timing and motives. This analysis ...
OpenAI reports Codex downloads exceed 1 million with over 1 million weekly active users, signaling a shift toward Cod...
Moody’s Analytics now sees a near-even chance of a U.S. recession within the next year, as energy shocks and a coolin...
ONE Sotheby’s International Realty expands into New Jersey by acquiring Callaway Henderson Sotheby’s International Re...
U.S. lenders are accelerating cash returns to shareholders after stress tests and capital rules ease. JPMorgan, Bank ...